Mucinex® for Treatment of Filamentary Keratitis

Filamentary Keratitis Clinical Trial

Official title:

Mucinex® for Treatment of Filamentary Keratitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02859246
• Other study ID #: 16-044H
• Status: Completed
• Phase: N/A
• Start date: September 2016
• Est. completion date: July 2018

Study information

• Verified date: February 2020
• Source: Massachusetts Eye and Ear Infirmary
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Description:

The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with filamentary keratitis

• 18 years and older

Exclusion Criteria:

• Active ocular surface infection of any type

• Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones

• Schirmer's test<3mm

• History of hypersensitivity to Mucinex®

• Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

Related Conditions & MeSH terms

• Filamentary Keratitis
• Keratitis

Intervention

Drug:
• Mucinex®
Mucinex®

Locations

Country	Name	City	State
United States	Massachusetts Eye and Ear Infirmary	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts Eye and Ear Infirmary

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Number of Corneal Filaments	Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.	baseline (day 1) and week 4
Secondary	Change in OSDI Score	Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline.; Total score ranges from 0-100. Lower OSDI scores means subjects are experiencing low ocular discomfort. High OSDI scores means subjects are experiencing high ocular discomfort.	baseline (day 1) and week 4

External Links

•   Related Info